Alkermes plc (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
$35.05
-$0.20(-0.70%)
At close: 4:00 PM EST
$35.05
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $36.48
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.65M
Market Cap
$5.84B
Enterprise Value$4.79B
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$70.00M
Price to Earnings (P/E)19.1
Beta0.77
Next Earnings
Apr 29, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding166,649,930
10 Day Avg. Volume3,585,691
30 Day Avg. Volume2,652,451
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda14.48
Forecast
1Y Price Target
$44.00Price Target Upside25.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$1.80B
Bulls Say, Bears Say
Bulls Say
Clinical Development And Regulatory ClarityRegulatory alignment on the orexin pivotal trial design and plans to start a late-stage registrational program reduce development uncertainty and improve the likelihood of a clear approval pathway and flexible labeling.
Mergers & Acquisitions / Market ValidationAcquisition interest from a major pharmaceutical company validates the orexin market opportunity and can expand commercial reach for the company's orexin programs beyond what a smaller biotech might achieve.
Product Differentiation And Commercial UptakeLumryz's once-nightly dosing combined with favorable payer coverage is driving disproportionate new-patient share and supports continued growth of the sleep franchise.
Bears Say
Balance Sheet And LeverageThe recent acquisition meaningfully increases company leverage, raising financial risk until the business reduces debt and potentially constraining strategic and investment flexibility.
Competitive PressureA much larger, better-financed competitor increases the risk that rivals accelerate development and capture non-narcolepsy indications, which could limit addressable market opportunities for the company's assets.
Revenue/guidance And Near-term ProfitabilityWeaker-than-expected sales for a core product together with higher operating expenses and modeling adjustments point to softer near-term revenue guidance and pressure on profitability and investor sentiment.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $36.48 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $5.84B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Apr 29, 2026 which is in 27 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Feb 25, 2026. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.41 by -$0.12.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is -0.54.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 166,649,930 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $0.29 in its last earnings report, missing expectations of $0.41. Following the earnings report the stock price went down -7.038%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (25.53% Upside)
$44.00 (25.53% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.74%
12-Months-Change
Fundamentals
Return on Equity
14.45%
Trailing 12-Months
Asset Growth
23.09%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by strong 2025 commercial performance (9% growth in proprietary portfolio), solid profitability and cash position, strategic acquisition of Avadel to enter sleep medicine (LUMRIZE), and clear pipeline momentum (elixorexant breakthrough designation and Phase 3 start). Key near‑term headwinds are acquisition accounting effects (inventory step‑up and amortization) producing an expected GAAP loss in 2026, materially higher R&D and SG&A to fund growth and integration, and financing‑related interest expense and debt. Management provided detailed 2026 guidance showing healthy adjusted EBITDA and revenue expansion, while acknowledging payer/competitive risks in the oxybate market and potential VIVITROL dynamics in 2027.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$44.00
▲(25.53% Upside)
Technical Analysis
Ownership Overview
1.42% Insiders
27.70% Mutual Funds
24.15% Other Institutional Investors
13.24% Public Companies and
Individual Investors